Lisa B Cohen1,2, Tracey H Taveira1,2,3, Sameed Ahmed M Khatana, Andrea G Dooley1,2, Paul A Pirraglia1,3, Wen-Chih Wu1,3. 1. Systems Outcomes and Quality in Chronic Disease and Rehabilitation, Research Enhancement Award Program, Providence VA Medical Center, Providence, Rhode Island (Dr Cohen, Dr Taveira, Dr Dooley, Dr Pirraglia, Dr Wu) 2. The Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island (Dr Cohen, Dr Taveira, Dr Dooley) 3. The Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island (Dr Taveira, Dr Pirraglia, Dr Wu)
Abstract
PURPOSE: To assess whether VA MEDIC-E (Veterans Affairs Multi-disciplinary Education and Diabetes Intervention for Cardiac risk reduction[EM DASH] Extended for 6 months), a pharmacist-led shared medical appointments program, could improve attainment of target goals for hypertension, hyperglycemia, hyperlipidemia, and tobacco use in patients with type 2 diabetes compared to standard primary care after 6 months of intervention. METHODS: A randomized, controlled trial of VA MEDIC-E (n = 50) versus standard primary care (n = 49) in veterans with type 2 diabetes, hemoglobin A1c (A1C) > 7%, blood pressure (BP) > 130/80 mmHg, and low density lipoprotein cholesterol (LDL-C) > 100mg/dl (2.59 mmol/l) in the previous 6 months was conducted. The VA MEDIC-E intervention consisted of 4 weekly group sessions followed by 5 monthly booster group sessions. Each 2-hour session included 1 hour of multidisciplinary diabetes specific healthy lifestyle education and 1 hour of pharmacotherapeutic interventions performed by a clinical pharmacist. Evaluation measures included lab values of A1C, LDL cholesterol, BP, and goal attainment of these values, and diabetes self-care behavior questionnaires at 6 months. RESULTS: The randomization groups were similar at baseline in all cardiovascular risk factors except for LDL, which was significantly lower in the MEDIC-E arm. At 6 months, significant improvements from baseline were found in the intervention arm for exercise, foot care, and goal attainment of A1C, LDL-C, and BP but not in the control arm. CONCLUSIONS: The results of this study demonstrate that the pharmacist-led group intervention program for 6 months was an efficacious and sustainable collaborative care approach to managing diabetes and reducing associated cardiovascular risk.
RCT Entities:
PURPOSE: To assess whether VA MEDIC-E (Veterans Affairs Multi-disciplinary Education and Diabetes Intervention for Cardiac risk reduction[EM DASH] Extended for 6 months), a pharmacist-led shared medical appointments program, could improve attainment of target goals for hypertension, hyperglycemia, hyperlipidemia, and tobacco use in patients with type 2 diabetes compared to standard primary care after 6 months of intervention. METHODS: A randomized, controlled trial of VA MEDIC-E (n = 50) versus standard primary care (n = 49) in veterans with type 2 diabetes, hemoglobin A1c (A1C) > 7%, blood pressure (BP) > 130/80 mmHg, and low density lipoprotein cholesterol (LDL-C) > 100mg/dl (2.59 mmol/l) in the previous 6 months was conducted. The VA MEDIC-E intervention consisted of 4 weekly group sessions followed by 5 monthly booster group sessions. Each 2-hour session included 1 hour of multidisciplinary diabetes specific healthy lifestyle education and 1 hour of pharmacotherapeutic interventions performed by a clinical pharmacist. Evaluation measures included lab values of A1C, LDL cholesterol, BP, and goal attainment of these values, and diabetes self-care behavior questionnaires at 6 months. RESULTS: The randomization groups were similar at baseline in all cardiovascular risk factors except for LDL, which was significantly lower in the MEDIC-E arm. At 6 months, significant improvements from baseline were found in the intervention arm for exercise, foot care, and goal attainment of A1C, LDL-C, and BP but not in the control arm. CONCLUSIONS: The results of this study demonstrate that the pharmacist-led group intervention program for 6 months was an efficacious and sustainable collaborative care approach to managing diabetes and reducing associated cardiovascular risk.
Authors: Cathy L Melvin; Melanie S Jefferson; LaShanta J Rice; Lynne S Nemeth; Andrea M Wessell; Paul J Nietert; Chanita Hughes-Halbert Journal: Prev Med Date: 2017-03-23 Impact factor: 4.018
Authors: Connor Drake; Julienne K Kirk; John B Buse; David Edelman; Christopher M Shea; Susan Spratt; Laura A Young; Anna R Kahkoska Journal: N C Med J Date: 2019 Sep-Oct
Authors: Krista K Proia; Anilkrishna B Thota; Gibril J Njie; Ramona K C Finnie; David P Hopkins; Qaiser Mukhtar; Nicolaas P Pronk; Donald Zeigler; Thomas E Kottke; Kimberly J Rask; Daniel T Lackland; Joy F Brooks; Lynne T Braun; Tonya Cooksey Journal: Am J Prev Med Date: 2014-06-02 Impact factor: 5.043
Authors: Ronald A Remick; Yuriko Araki; Robin Bruce; Chris Gorman; Judy Allen; Abigail K Remick; Scott A Lear Journal: Can J Psychiatry Date: 2014-04 Impact factor: 4.356
Authors: David Edelman; Jennifer M Gierisch; Jennifer R McDuffie; Eugene Oddone; John W Williams Journal: J Gen Intern Med Date: 2014-08-09 Impact factor: 5.128